Product nameGefitinib, EGFR tyrosine kinase inhibitor
DescriptionOrally active, potent, selective EGFR tyrosine kinase inhibitor
- ZD 1839
Orally active, potent, selective EGFR (Epidermal growth factor receptor) tyrosine kinase inhibitor (IC50 = 33 nM). Inhibits EGF-stimulated EGFR autophosphorylation and inhibits tumor growth in vivo. Enhances efficacy of cytotoxic agents. Inhibits growth factor production and angiogenesis. Clinically useful anticancer agent.
Storage instructionsShipped at Room Temperature. Store at -20°C. Store under desiccating conditions.
Solubility overviewSoluble in DMSO to 100 mM
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
This product has been referenced in:
- McKillop D et al. Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor. Mol Cancer Ther 4:641-9 (2005). Read more (PubMed: 15827338) »
- Wakeling AE et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 62:5749-54 (2002). Read more (PubMed: 12384534) »
- Ciardiello F et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 7:1459-65 (2001). Read more (PubMed: 11350918) »
- Ciardiello F et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 6:2053-63 (2000). Read more (PubMed: 10815932) »
- Baselga J & Averbuch SD ZD1839 ('Iressa') as an anticancer agent. Drugs 60 Suppl 1:33-40; discussion 41-2 (2000). Read more (PubMed: 11129170) »